On the track of the deadly parasite Leishmania

May 14, 2014

Leishmaniasis is one of the most underreported and insufficiently monitored diseases in the world. According to the WHO more than 300.000 people are infected annually with the most severe form of this disease - kala-azar. The treatment against this forgotten disease becomes increasingly difficult, and sometimes impossible as the parasites developed resistance against the existing drugs. Now scientists from Europe, India and Nepal have joined forces within the European Research Project Kaladrug-R to regain control against this disease and develop new effective clinical tools.

Leishmaniasis is one of the most underreported and insufficiently monitored diseases in the world affecting mainly the poorest and most disadvantaged people on the Indian Subcontinent, Latin America and East Africa. The disease is caused by tiny , the Leishmania, and transmitted by the bite of an infected sandfly.

Scientists at the Institute of Tropical Medicine in Antwerp, Belgium, are investigating why more and more Leishmania parasites develop resistance against existing drugs. Within the European Research Project Kaladrug-R partners from Europe, India and Nepal are developing simple clinical tools with the aim to use them in the high-risk areas on the Indian Subcontinent. This way, the scientists in India will be able to monitor the effectiveness of the drugs, and the degree of infection, and therefore the spread of drug resistance.

In its most severe form – the visceral Leishmanisis called kala-azar – the parasites seize the internal organs, and without treatment it will lead to death. That is why this form of the disease is stated to be the second largest parasitic killer after malaria. The World Health Organisation (WHO) is reporting 300,000 new cases annually.

The video will load shortly

As the drug-resistant parasites become more widespread, the treatment against this forgotten disease becomes increasingly difficult, and sometimes impossible. Now, only the protection against the bites of sandflies and new innovative research could help to regain control against this deadly disease.

Explore further: Kala-azar treatment failing in Nepal

Related Stories

Kala-azar treatment failing in Nepal

March 1, 2013
In a recent study, scientists have concluded that the cure rates of Miltefosine, the only oral drug for visceral leishmaniasis available, have significantly decreased. Miltefosine was introduced in the Indian subcontinent ...

Parasite surveillance to support policy against drug resistance

May 14, 2014
Leishmaniasis is a tropical disease known in Europe because it affects dogs. It is caused by the Leishmania parasite carried by sandflies. However, several types of the parasite also affect humans in several regions in the ...

Leishmania parasites with greater infectivity associated with treatment failure

October 8, 2013
Relapses after treatment for Leishmania infection may be due to a greater infectivity of the parasite rather than drug resistance, as has been previously thought, according to a study published in mBio, the online open-access ...

Arsenic in India's water could cause resistance to visceral leishmaniasis treatment

October 29, 2013
(Medical Xpress)—Every year, visceral leishmaniasis infects about 500,000 people and kills about 41,000. Most deaths occur in India's Bihar region, where there is a high level of resistance to the antimony compounds used ...

Belgian scientists develop way to detect superparasites

July 19, 2012
Belgian scientists of the Institute of Tropical Medicine (ITM) in Antwerp, Belgium made a breakthrough in bridging high tech molecular biology research on microbial pathogens and the needs of the poorest of the poor. After ...

Combination therapies are a cost-effective alternative when treating visceral leishmaniasis

September 16, 2013
Visceral leishmaniasis is the second-deadliest parasitic disease after malaria. Each year, thousands fall victim among poor and marginalised populations in low-income countries. Filip Meheus is the first to detail the economic ...

Recommended for you

Male hepatitis B patients suffer worse liver ailments, regardless of lifestyle

July 25, 2017
Why men with hepatitis B remain more than twice as likely to develop severe liver disease than women remains a mystery, even after a study led by a recent Drexel University graduate took lifestyle choices and environments ...

Researchers report new system to study chronic hepatitis B

July 25, 2017
Scientists from Princeton University's Department of Molecular Biology have successfully tested a cell-culture system that will allow researchers to perform laboratory-based studies of long-term hepatitis B virus (HBV) infections. ...

Mind-body therapies immediately reduce unmanageable pain in hospital patients

July 25, 2017
Mindfulness training and hypnotic suggestion significantly reduced acute pain experienced by hospital patients, according to a new study published in the Journal of General Internal Medicine.

Research examines lung cell turnover as risk factor and target for treatment of influenza pneumonia

July 24, 2017
Influenza is a recurring global health threat that, according to the World Health Organization, is responsible for as many as 500,000 deaths every year, most due to influenza pneumonia, or viral pneumonia. Infection with ...

Scientists propose novel therapy to lessen risk of obesity-linked disease

July 24, 2017
With obesity related illnesses a global pandemic, researchers propose in the Journal of Clinical Investigation using a blood thinner to target molecular drivers of chronic metabolic inflammation in people eating high-fat ...

Raccoon roundworm—a hidden human parasite?

July 24, 2017
The raccoon that topples your trashcan and pillages your garden may leave more than just a mess. More likely than not, it also contaminates your yard with parasites—most notably, raccoon roundworms (Baylisascaris procyonis).


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.